NCT02226172 - Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

December 14, 2016

Study Completion Date

January 31, 2018

Conditions

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG

Glasdegib (PF-04449913)

Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.

DRUG

Placebo

Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.

Trial Locations (19)

10021

Weill Cornell Medical College - New York-Presbyterian Hospital, New York

10032

Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York

10065

Weill Cornell Medical College-New York Presbyterian Hospital, New York

44195

Cleveland Clinic - Taussig Cancer Institute, Cleveland

48109

University of Michigan, Ann Arbor

84112

Huntsman Cancer Institute-University of Utah, Salt Lake City

University of Utah, Huntsman Cancer Hospital, Salt Lake City

85054

Mayo Clinic Building - Phoenix, Phoenix

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic, Scottsdale

92037

UCSD Medical Center Clinical Laboratory - La Jolla, La Jolla

92103

UC San Diego Medical Center- Hillcrest, San Diego

6500017

Kobe University Hospital, Kobe

92037-0845

UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla

92093-0698

University of California San Diego (UCSD) Moores Cancer Center, La Jolla

53226-3522

Froedtert Hospital and Medical College of Wisconsin, Milwaukee

565-0871

Osaka University Hopsital, Suita-Shi

113-8431

Juntendo University Hospital, Bunkyo-ku

160-0023

Tokyo Medical University Hospital, Tokyo